|
Market Closed -
NYSE
16:00:02 2026-09-21 EDT
|
5-day change | 1st Jan Change | ||
| 140.98 USD | +0.43% |
|
+1.43% | +2.26% |
| 09-21 | Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations | MT |
| 09-21 | Pharma sector doubles down on AI to slash costs, timelines | RE |
Company Valuation: Novartis AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 196,458 | 194,448 | 207,167 | 195,514 | 266,003 | 268,816 | - | - |
| Change | - | -1.02% | 6.54% | -5.62% | 36.05% | 1.06% | - | - |
| Enterprise Value (EV) 1 | 204,649 | 203,482 | 219,178 | 213,458 | 289,870 | 300,395 | 296,701 | 289,692 |
| Change | - | -0.57% | 7.71% | -2.61% | 35.8% | 3.63% | -1.23% | -2.36% |
| P/E | 8.2x | 28.3x | 14.1x | 16.5x | 19.2x | 20x | 16.8x | 14.7x |
| PBR | 2.9x | 3.23x | 4.41x | 4.52x | 5.73x | 5.68x | 5.26x | 4.72x |
| PEG | - | -0.4x | 0x | -1x | 0.9x | -11.87x | 0.9x | 1x |
| Capitalization / Revenue | 3.81x | 3.85x | 4.44x | 3.78x | 4.69x | 4.66x | 4.38x | 4.12x |
| EV / Revenue | 3.96x | 4.03x | 4.7x | 4.13x | 5.11x | 5.21x | 4.84x | 4.44x |
| EV / EBITDA | 11.2x | 10.9x | 12.2x | 10.2x | 12.4x | 12.9x | 11.8x | 10.7x |
| EV / EBIT | 12.3x | 12.2x | 13.4x | 10.9x | 13.2x | 13.8x | 12.6x | 11.3x |
| EV / FCF | 15.4x | 17x | 16.6x | 13.1x | 16.5x | 19.3x | 17.5x | 15.1x |
| FCF Yield | 6.49% | 5.87% | 6.01% | 7.61% | 6.07% | 5.17% | 5.71% | 6.6% |
| Dividend per Share 2 | 3.36 | 3.5 | 3.823 | 3.856 | 4.762 | 4.352 | 4.543 | 4.729 |
| Rate of return | 3.83% | 3.87% | 3.79% | 3.94% | 3.44% | 3.08% | 3.21% | 3.34% |
| EPS 2 | 10.71 | 3.19 | 7.15 | 5.92 | 7.21 | 7.089 | 8.41 | 9.636 |
| Distribution rate | 31.4% | 110% | 53.5% | 65.1% | 66% | 61.4% | 54% | 49.1% |
| Net sales 1 | 51,626 | 50,545 | 46,660 | 51,722 | 56,674 | 57,652 | 61,332 | 65,257 |
| EBITDA 1 | 18,246 | 18,613 | 17,937 | 21,006 | 23,415 | 23,242 | 25,221 | 27,199 |
| EBIT 1 | 16,588 | 16,665 | 16,372 | 19,494 | 21,889 | 21,806 | 23,638 | 25,571 |
| Net income 1 | 24,021 | 6,955 | 14,854 | 11,939 | 13,967 | 14,196 | 15,754 | 17,572 |
| Net Debt 1 | 8,191 | 9,034 | 12,011 | 17,944 | 23,867 | 31,579 | 27,885 | 20,876 |
| Reference price 2 | 87.82 | 90.40 | 100.79 | 97.79 | 138.63 | 141.43 | 141.43 | 141.43 |
| Nbr of stocks (in thousands) | 2,237,092 | 2,150,980 | 2,055,460 | 1,999,270 | 1,918,792 | 1,900,715 | - | - |
| Announcement Date | 2/2/22 | 2/1/23 | 1/31/24 | 1/31/25 | 2/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.78x | 11.92x | 24.16x | 0.6% | 1,038B | |
| 30.03x | 6.68x | 18.7x | 1.99% | 649B | |
| 33.38x | 7.81x | 16.15x | 2.6% | 467B | |
| 19.33x | 4.72x | 11.71x | 2.81% | 355B | |
| 19.72x | 5.16x | 12.79x | 3.11% | 269B | |
| 21.26x | 4.42x | 12.58x | 1.99% | 260B | |
| 24.43x | 6.42x | 11.43x | 2.62% | 213B | |
| 12.52x | 4.56x | 9.46x | 4.01% | 176B | |
| -45.4x | 6.61x | 25.81x | 2.19% | 187B | |
| Average | 16.45x | 6.48x | 15.87x | 2.44% | 401.68B | |
| Weighted average by Cap. | 23.72x | 7.74x | 17.86x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- NOVN Stock
- NVS Stock
- Valuation Novartis AG
Select your edition
All financial news and data tailored to specific country editions
